| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966736 | Vaccine | 2013 | 7 Pages |
Abstract
The diminished cellular reactivity to VZV has to be considered in SOT patients receiving immunosuppressive treatments when evaluating immunity against VZV. IgG antibody avidity and VZV-specific cellular responses may serve as additional markers to evaluate immunity against VZV in SOT recipients. The role of wild-type exposures and endogenous VZV re-activation on long-term immunity in SOT patients has to be awaited to establish recommendations for vaccine spacing in these patients, considering immunogenicity and safety aspects.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Martina Prelog, Jörn Schönlaub, Verena Jeller, Giovanni Almanzar, Kerstin Höfner, Saskia Gruber, Thomas Eiwegger, Reinhard Würzner,